Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$3.36 - $6.37 $5.89 Million - $11.2 Million
-1,753,800 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$4.6 - $7.8 $954,522 - $1.62 Million
-207,505 Reduced 10.58%
1,753,800 $1.21 Million
Q4 2021

Feb 14, 2022

SELL
$6.1 - $10.2 $17,720 - $29,630
-2,905 Reduced 0.15%
1,961,305 $1.3 Million
Q3 2021

Nov 12, 2021

BUY
$8.2 - $12.4 $734,933 - $1.11 Million
89,626 Added 4.78%
1,964,210 $1.82 Million
Q2 2021

Aug 13, 2021

BUY
$11.8 - $18.2 $22.1 Million - $34.1 Million
1,874,584 New
1,874,584 $2.23 Million

About Cellectar Biosciences, Inc.


  • Ticker CLRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,114,290
  • Market Cap $12.5M
  • Description
  • Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...
More about CLRB
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.